Elevation Oncology
Seribantumab, an ErbB3 bispecific antibody therapeutic targeting NRG1 fusion-driven solid tumors
- Sector
- Biotech
- Founded
- 2019
- Latest Form D
- $65M, Nov 2020
- Total capital
- $70.5M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $70.5M
- 2 Form D · last Nov 2020
- 71 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 5 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$65M
- Private capital raisedForm D · SEC · 1st filing$5.5M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Andrew PhillipsDirectorNamed in SEC Form D filings
- Colin WalshDirectorNamed in SEC Form D filings
- Lori HuDirectorNamed in SEC Form D filings
- Richard GasterDirectorNamed in SEC Form D filings
- Shawn LelandExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Steven ElmsExecutive Officer, Director, PromoterNamed in SEC Form D filings
Show all 7 people
- Timothy ClacksonDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 5- PendingAntibodies Against The Ectodomain Of ERBB3 And Uses ThereofUSPTOApplication 18630602
- PendingDosage And Administration Of ANTI-ERBB3 (HER3) Monoclonal Antibodies To Treat Tumors Associated With Neuregulin 1 (NRG1) Gene FusionsUSPTOApplication 17691645
- PendingAntibodies Against The Ectodomain Of ERBB3 And Uses ThereofUSPTOApplication 17376627
Show all 5 patent records
- Antibodies Against The Ectodomain Of ERBB3 And Uses ThereofOct 31, 2024 · Application 18630602Pending
- Dosage And Administration Of ANTI-ERBB3 (HER3) Monoclonal Antibodies To Treat Tumors Associated With Neuregulin 1 (NRG1) Gene FusionsSep 15, 2022 · Application 17691645Pending
- Antibodies Against The Ectodomain Of ERBB3 And Uses ThereofJun 30, 2022 · Application 17376627Pending
- Dosage And Administration Of ANTI-ERBB3 (HER3) Monoclonal Antibodies To Treat Tumors Associated With Neuregulin 1 (NRG1) Gene FusionsApplication PCTUS2022019745Pending
- Dosage And Administration Of ANTI-ERBB3 (HER3) Monoclonal Antibodies To Treat Tumors Associated With Neuregulin 1 (NRG1) Gene FusionsApplication 63159575Pending
Related companies, and why
- TNF Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Vera Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Epicrispr Biotechnologies, Inc.Similar federal contract value in Biotech · null in contracts
- NANOMATRONIX LLCSimilar federal contract value in Biotech · null in contracts
- Neon TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Dimension TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .